Biocon Limited

BSE: 532523 NSE: BIOCON
Biocon Limited - pharma in Bengaluru, Karnataka, India. FY 2026 financials & compliance.
CIN L24234KA1978PLC003417 Incorporated 29 November 1978 ROC Bangalore HQ Bengaluru, Karnataka, India
Active Listed - NSE: BIOCON · BSE: 532523 Public Limited Company pharma
Data last updated
Market Cap
₹63,069 Cr
BIOCON · NSE
Share Price
₹382.15
-1.25% today
Revenue
₹16,927 Cr
FY 2025-26 · +14.7% YoY
EBITDA
₹3,052 Cr
Margin 18.0%
Net Profit
₹389 Cr
FY 2025-26 · -59.3% YoY
P/E (TTM)
88.2x
P/B 1.9x
ROE
1.3%
ROCE 3.8%
Debt / Equity
0.61
Interest cover 90.4x

About Biocon Limited

Data last updated: 27 September 2026

Biocon Limited is a public limited company based in Bengaluru, Karnataka, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 29 November 1978, the company has been in operation for over 48 years.

Registered with ROC Bangalore under CIN L24234KA1978PLC003417. Listed on BSE: 532523 and NSE: BIOCON.

Capital: an authorised share capital of ₹900 Cr and a paid-up capital of ₹814.85 Cr. It is led by directors including Ravi Rasendra Mazumdar and Bobby Kanubhai Parikh.

Last AGM: 08 August 2025. Financial statements filed for year ended 31 March 2025. Office: 20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹16,927 Cr, a growth of 10.91% compared to the previous year. The net worth stands at ₹34,032 Cr (up 57.23% YoY). Total assets are valued at ₹53,491 Cr (up 8.01% YoY).

The company has a workforce of approximately 4,020 employees as per the latest available data. Its group structure includes 6 subsidiaries.

The company is associated with 1 brand - Biocon. As per MCA filings, the company has open charges of ₹207.63 Cr and satisfied charges of ₹2,010.35 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.

Company Details of Biocon Limited
CIN L24234KA1978PLC003417
Registration Number 003417
Incorporation Date 29 November 1978
ROC Bangalore
Listing Status Listed (BSE: 532523, NSE: BIOCON)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Shreehas Pradeep Tambe Managing Director Kiran Mazumdar Shaw Whole-Time Director Ravi Rasendra Mazumdar Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    biocon.com
  • Social Media
  • Registered Address
    20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100
  • Industry
    Pharma, Drug Formulation & Development
Company report
Biocon Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Biocon Limited report

Financials, compliance, directors, charges, ownership and filings for Biocon Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Biocon Limited

Biocon Limited has one previous CIN (Corporate Identification Number): L00309KA1978PLC003417. The current CIN is L24234KA1978PLC003417, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24234KA1978PLC003417 Current
L00309KA1978PLC003417 Previous

Associated Brands with Biocon Limited

Biocon Limited operates one associated brand: Biocon. These brands represent Biocon Limited's diversified market presence and brand portfolio.

Brand Description Website
Biocon
Drug R&D services are provided for multiple therapeutic areas. biocon.com

Business Activity of Biocon Limited

Biocon Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Biocon Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Biocon Limited

Biocon Limited is audited by BSR & Co. LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
BSR & Co. LLP Locked Locked Locked
Premium access

Complete auditor history for Biocon Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Biocon Limited

Biocon Limited is currently managed by 9 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ravi Rasendra Mazumdar
Also directs: Glenloch Properties Llp
Director 08 Aug 2000 26 Years 1 Months Current
Bobby Kanubhai Parikh
Also directs: Avaana Capital Advisors Llp, Hindustan Unilever Limited, Indostar Capital Finance Limited and 4 more
Director 27 Jul 2018 8 Years 2 Months Current
Kiran Mazumdar Shaw
Also directs: Biocon Biologics Limited, Glenloch Properties Llp, Trent Limited and 5 more
Whole-Time Director 01 Apr 2010 16 Years 5 Months Current
Eric Vivek Mazumdar Director 01 Nov 2021 4 Years 10 Months Current
Naina Lal Kidwai
Also directs: Upl Limited, Gland Pharma Ltd, Nayara Energy Limited and 1 more
Director 28 Apr 2022 4 Years 4 Months Current
Atul Dhawan
Also directs: Uti Asset Management Company Limited, National Investment And Infrastructure Fund Limited
Director 16 May 2024 2 Years 4 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Biocon Limited FY 2025-26 filings available

Biocon Limited reported revenue of ₹16,927 Cr (up 10.91% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹16,927 Cr
+10.9% YoY
EBITDA
₹3,052 Cr
-3.6% YoY
Profit After Tax
₹389 Cr
-59.3% YoY
Net Worth
₹34,032 Cr
+57.2% YoY
Total Assets
₹53,490 Cr
+8.0% YoY
Total Debt
₹15,434 Cr
-15.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+14.7%+4.7%+26.7%+39.6%+17.3%+17.8%+14.7%
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Profit before tax4481,8871,5258979831,0681,186
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
Balance sheet
Total assets53,49049,52343,17245,67017,44015,68511,816
Net worth34,03221,64419,78417,8678,4327,6276,706
Total debt15,43418,36216,27718,0195,1474,4812,715
Cash & bank3,1944,1202,2592,4001,7482,015999
Net working capital6,5726,9232,3575,0164,2633,5871,869
Cash flow
Cash from operations1,9944,0612,9541,8521,1771,1601,283
Cash from investing(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Cash from financing(924)(1,854)(2,333)13,0492422,564388
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,3364,5174,1734,2963,9424,4173,8213,590
Revenue growth (YoY)+9.8%+2.9%+9.3%+20.2%+15.8%+12.8%+6.3%+4.5%
Other income54.5052.5011793.0079.7057.3052.9058.50
EBITDA8349405408247491,078752685
EBITDA margin+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%+19.3%
Depreciation547513515473455436425420
Interest213232210272277212223226
Profit before tax128248(67.80)17196.9048715698.40
Tax(9.20)48.90(16.00)38.507.7027.4074.8071.30
Net profit137199(51.80)13389.2045981.1027.10
EPS (₹)0.870.791.070.650.262.870.21(0.13)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+13.0%+10.8%-5.3%+17.4%-2.3%+0.8%+8.1%
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Profit before tax51.006611502,971140359553
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
Balance sheet
Total assets28,35714,49213,07812,3338,2798,0247,584
Net worth27,08011,52410,91210,9168,0937,9077,537
Total debt1,1532,8762,0431,30176.901.904.00
Cash & bank91.70250586720689601375
Net working capital1,2101,0552,0071,5481,5501,2801,218
Cash flow
Cash from operations(180)624(123)21947.60478387
Cash from investing(6,580)(992)(295)(1,173)(302)(628)(189)
Cash from financing6,6024953441,03911227.80(129)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue624605621583537644563525
Revenue growth (YoY)+16.3%-6.1%+10.4%+11.0%+5.2%+20.9%0.0%+1.3%
Other income64.8049.8074.8013461.3062.7067273.50
Total expenses564544744530516582532488
EBITDA60.8060.50(123)52.9020.6062.0031.3037.60
EBITDA margin+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%+7.2%
Depreciation38.4036.2034.0033.8033.3033.0033.8030.50
Interest17.3016.702.3067.2056.2056.7065.3059.70
Profit before tax69.9057.40(84.50)85.70(7.60)35.0060420.90
Tax17.706.40(8.10)14.800.7013.8019.9017.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 27 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,3364,5174,1734,2963,9424,4173,8213,590
Revenue growth (YoY)+9.8%+2.9%+9.3%+20.2%+15.8%+12.8%+6.3%+4.5%
Other income54.5052.5011793.0079.7057.3052.9058.50
EBITDA8349405408247491,078752685
EBITDA margin+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%+19.3%
Depreciation547513515473455436425420
Interest213232210272277212223226
Profit before tax128248(67.80)17196.9048715698.40
Tax(9.20)48.90(16.00)38.507.7027.4074.8071.30
Net profit137199(51.80)13389.2045981.1027.10
EPS (₹)0.870.791.070.650.262.870.21(0.13)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+14.7%+4.7%+26.7%+39.6%+17.3%+17.8%+14.7%
Other income3421,305866376213267229
Total expenses13,87512,09511,5539,1216,5325,5704,726
Employee cost3,5083,1442,6642,1811,8801,7411,459
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Depreciation1,9571,6871,5691,113814715552
Interest99089797441967.6057.7064.90
Profit before tax4481,8871,5258979831,0681,186
Tax79.10457227254212222315
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus33,32921,12219,18317,2677,8327,0276,106
Shareholders' funds (net worth)34,03221,64419,78417,8678,4327,6276,706
Minority interest2,5906,0685,4914,6221,038881677
Secured loans11,29312,70112,23013,7952,6222,2952,042
Unsecured loans4,1415,6614,0474,2242,5252,186674
Total debt15,43418,36216,27718,0195,1474,4812,715
Total liabilities53,49049,52343,17245,67017,44015,68511,816
Assets
Gross block48,07940,80437,93035,32111,23310,2219,147
Net block36,48631,96330,64429,4686,5696,3645,971
Capital work in progress6,9878,5087,9937,3174,1102,8002,196
Investments1,7791,1271,0002,0691,5881,952966
Inventories6,0864,9314,9444,2442,2981,8671,436
Sundry debtors5,9875,4886,2313,5732,0581,5031,224
Cash & bank balances3,1944,1202,2592,4001,7482,015999
Loans & advances1,2241,3001,4307901,0611,006809
Total current assets16,49015,83914,86411,0087,1656,3924,467
Total current liabilities9,9188,91612,5075,9922,9012,8052,598
Net working capital6,5726,9232,3575,0164,2633,5871,869
Total assets53,49049,52343,17245,67017,44015,68511,816
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,9249201,300654897825659
Net cash from operating activities1,9944,0612,9541,8521,1771,1601,283
Net cash from investing activities(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Net cash from financing activities(924)(1,854)(2,333)13,0492422,564388
Net change in cash(812)2,004(380)641(243)72.30165
Closing cash3,1944,1202,2592,4001,7482,015999
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%+14.3%
EBITDA growth-3.6%-1.1%+56.0%+24.3%+5.0%-0.1%+13.0%
PBT growth-76.3%+23.7%+70.0%-8.8%-7.9%-10.0%-2.4%
Net income growth-59.3%-2.3%+41.2%-7.3%+2.4%+5.8%-4.8%
Revenue CAGR (3Y)+14.9%+23.1%+27.4%+21.1%+14.1%+20.1%+17.4%
EBITDA CAGR (3Y)+14.1%+24.2%+26.7%+9.3%+5.8%+23.8%+17.1%
Profitability & leverage
Net income margin+2.2%+9.4%+8.8%+5.8%+9.4%+11.9%+13.8%
Return on capital employed+3.8%+6.9%+6.4%+5.7%+7.6%+8.7%+12.2%
Return on net worth+1.3%+6.9%+6.9%+6.6%+10.8%+11.8%+13.6%
Debt / equity0.610.840.910.880.600.500.40
Long-term debt / equity0.460.670.770.750.500.400.32
Interest cover90.3860.6659.6344.568.076.726.35
Efficiency & per share
Fixed asset turnover0.380.390.400.480.760.740.78
Inventory turnover3.073.093.213.423.934.335.11
Debtors turnover2.952.603.013.974.605.245.01
EPS (₹)2.388.448.523.855.406.176.24
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)210.60180.92164.77148.8170.2363.5555.87
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue624605621583537644563525
Revenue growth (YoY)+16.3%-6.1%+10.4%+11.0%+5.2%+20.9%0.0%+1.3%
Other income64.8049.8074.8013461.3062.7067273.50
Total expenses564544744530516582532488
EBITDA60.8060.50(123)52.9020.6062.0031.3037.60
EBITDA margin+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%+7.2%
Depreciation38.4036.2034.0033.8033.3033.0033.8030.50
Interest17.3016.702.3067.2056.2056.7065.3059.70
Profit before tax69.9057.40(84.50)85.70(7.60)35.0060420.90
Tax17.706.40(8.10)14.800.7013.8019.9017.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+13.0%+10.8%-5.3%+17.4%-2.3%+0.8%+8.1%
Other income3208502083,134187150366
Total expenses2,3352,0671,8651,9691,6771,7161,702
Employee cost467501452434368390345
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Depreciation13712812111710810498.00
Interest14223719969.600.400.401.20
Profit before tax51.006611502,971140359553
Tax13.8051.6031.0012353.6078.30112
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus26,23711,00210,31210,3167,4937,3076,937
Shareholders' funds (net worth)27,08011,52410,91210,9168,0937,9077,537
Secured loans1752,2522,0411,29875.900.000.00
Unsecured loans9786242.003.501.001.904.00
Total debt1,1532,8762,0431,30176.901.904.00
Total liabilities28,35714,49213,07812,3338,2798,0247,584
Assets
Gross block3,2352,8392,5872,4802,2772,0981,993
Net block1,3811,114958961870798793
Capital work in progress541701560344285179152
Investments24,97811,3839,3189,2715,2805,4134,953
Inventories875836665560542431535
Sundry debtors1,0038291,048658701588573
Cash & bank balances91.70250586720689601375
Loans & advances146255399307209210462
Total current assets2,1162,1702,6972,2452,1401,8301,945
Total current liabilities9061,115690697590550727
Net working capital1,2101,0552,0071,5481,5501,2801,218
Total assets28,35714,49213,07812,3338,2798,0247,584
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash250122197111254375306
Net cash from operating activities(180)624(123)21947.60478387
Net cash from investing activities(6,580)(992)(295)(1,173)(302)(628)(189)
Net cash from financing activities6,6024953441,03911227.80(129)
Net change in cash(158)127(74.30)85.60(142)(122)69.30
Closing cash91.70250586720689601375
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%+11.4%
EBITDA growth-93.7%-33.1%+1017.9%-61.5%-80.5%+9.3%+36.0%
PBT growth-92.3%+339.7%-94.9%+2026.8%-61.1%-35.1%+2.9%
Net income growth+9998.0%-+9998.0%--70.0%-8.9%-6.6%
Revenue CAGR (3Y)+5.6%+8.9%+1.6%+0.1%-0.9%-5.7%-8.4%
EBITDA CAGR (3Y)-22.4%+42.2%-5.6%-56.5%-33.8%-0.6%-21.5%
Profitability & leverage
Net income margin+1.6%+27.2%+5.6%+142.9%+5.0%+13.8%+22.2%
Return on capital employed+1.6%+2.1%+2.6%+1.5%+1.7%+4.6%+5.2%
Return on net worth+0.9%-0.5%+1.0%-0.1%+1.1%+3.6%+4.2%
Debt / equity0.100.220.150.070.000.000.01
Long-term debt / equity0.060.190.150.070.000.000.01
Interest cover-112.75493.54140.40-74.52-0.850.190.64
Efficiency & per share
Fixed asset turnover0.770.830.840.840.790.990.87
Inventory turnover2.742.993.473.623.584.202.98
Debtors turnover2.562.392.492.932.703.492.70
EPS (₹)0.235.070.9923.720.722.343.67
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)166.8596.6390.8890.9167.4065.8862.80
Want more history and ratios?
You're viewing the latest exchange-filed financials for Biocon Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Biocon Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 44.70%, foreign institutional investors hold 8.10%, domestic institutional investors hold 23.40%, retail and other public shareholders hold 23.80% of Biocon Limited.

Promoters: 44.70%DII (Domestic Institutional): 23.40%FII (Foreign Institutional): 8.10%Retail & Others: 23.80%
Jun 2026
QUARTER
44.70% Promoters
23.40% DII (Domestic Institutional)
8.10% FII (Foreign Institutional)
23.80% Retail & Others
Promoter holding - history
Now 44.70% · Jun 2026High 54.40% · Sep 2025Low 44.70% · Jun 2026
43%46.3%49.5%52.8%56%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 54.40%Dec 2025: 54.40%Mar 2026: 44.90%Jun 2026: 44.70%54.40%44.70%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters44.70%44.90%54.40%54.40%
Public55.30%55.10%45.60%45.60%

Group Structure of Biocon Limited

Biocon Limited has 6 subsidiary companies. This group structure data is as of FY 2022. The corporate group structure reflects Biocon Limited's business expansion strategy and organizational complexity.

6
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Syngene International Limited L85110KA1993PLC014937 -
Biocon Biologics Limited U24119KA2016FLC093936 -
Biocon Pharma Limited U24232KA2014PLC077036 -
Biocon Biosphere Limited U24304KA2019PLC130965 -
Biofusion Therapeutics Limited U73100KA2021PLC145487 -
Biocon Academy U80301KA2013NPL072272 -

Showing major subsidiaries. Total: 6.

Charges & Borrowings of Biocon Limited

Open charges
₹207.63 Cr
Satisfied charges
₹2,010.35 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹197.50 Cr
Department of Biotechnology₹10.13 Cr
Latest charge details
DateLenderAmountStatus
07 Nov 2022 Hdfc Bank Limited ₹197.5 Cr Open
29 Jun 2011 Department of Biotechnology ₹4.43 Cr Open
12 Nov 2010 Department of Biotechnology ₹5.71 Cr Open
28 Apr 2023 Others ₹500 Cr Satisfied
12 Feb 2023 Others ₹1,070 Cr Satisfied

Total charge records: 9 View all charges

Employees and EPFO Compliance at Biocon Limited

Biocon Limited has a workforce of 4,020 employees as of Apr 08, 2024.

Employee count
4,020
Active EPFO establishments
1
Employee growth
5.87%
Premium access

Employee and EPFO history for Biocon Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Biocon Limited

Premium access

GST registrations and filing compliance for Biocon Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Biocon Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Biocon Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Biocon Limited

Premium access

MSME payment history for Biocon Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Biocon Limited

Premium access

Corporate group structure for Biocon Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Biocon Limited

Premium access

MCA filings and documents for Biocon Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Biocon Limited

Directors
06 May 2026
Shreehas Pradeep Tambe was appointed as a Ceo on 06 May 2026 & has been associated with this company since 4 months 24 days.
Directors
22 Apr 2026
Kedar Upadhye was appointed as a Cfo on 22 Apr 2026 & has been associated with this company since 5 months 7 days.
Directors
01 Apr 2026
Shreehas Pradeep Tambe was appointed as a Managing Director on 01 Apr 2026 & has been associated with this company since 5 months 28 days.
Charges
05 Jan 2026
A charge registered on 28 Apr 2023 via Charge ID 100775922 with Others was fully satisfied on 05 Jan 2026.
Charges
01 Oct 2025
A charge registered on 12 Feb 2023 via Charge ID 100825122 with Others was fully satisfied on 01 Oct 2025.
Directors
13 Sep 2025
Rajesh Umakant Shanoy was appointed as a Company Secretary on 13 Sep 2025 & has been associated with this company since 1 year 14 days.

Recent News on Biocon Limited

Frequently Asked Questions about Biocon Limited

Biocon Limited is an active public limited company in the pharma sector based in Bengaluru, Karnataka, India. It was incorporated on 29 November 1978 (48+ years old) and is registered under CIN L24234KA1978PLC003417. Listed on BSE: 532523 and NSE: BIOCON. The company has 4,020 employees.

Biocon Limited reported revenue of ₹16,927 Cr for FY 2025-26 (up 10.91% YoY) based on consolidated financials.

The current directors of Biocon Limited are:

The primary industry of Biocon Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Biocon Limited is listed on both BSE (code: 532523) and NSE (symbol: BIOCON).

Biocon Limited can be reached at the registered office: 20Th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100, or through the website biocon.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available